Institut de Cancerologie du Gard - CHU Caremeau ( Site 0490)

Nîmes, Gard 30029

0 studies enrolling now · 1 studies all time

What they study most

Urinary Bladder Cancer, Muscle-invasive

Studies at this site

• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) — Running, not enrolling